Skip to main content
. 2006 Jul 19;2006(3):CD006148. doi: 10.1002/14651858.CD006148

Delaugerre 2001.

Methods N=20 
 Non randomized 
 Fup=unclear
Participants Eligibility:‐ 
 Treatment failure 
 VL>10,000 copies/ml for 36 months, 
 CDC stage C 80% patients; 
 Median ART 73months(29‐118) 
 Median CD4 200 cells/mm3; 
 Baseline median VL 160, 000 cop/ml
Interventions 8 wks TI (4‐24 wks)
Outcomes STI arm: 
 Viral reversion: 55% participants
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Allocation concealment? Unclear risk D ‐ Not used